Clinical Innovation UNC Health Expands Use of Abridge AI Technology to Enhance Patient and Clinician Experience Clinical Innovation UNC Health, one of the largest and most comprehensive healthcare systems in the Southeast, is taking a significant step toward improving the…
Understanding Cell and Gene Therapy Trials for Pediatric Rare Diseases: Join the Upcoming Xtalks Webinar Cell and gene therapy (CGT) has emerged as a promising treatment for rare diseases, particularly for pediatric populations where few treatment options exist. The increasing…
Genvax Technologies Receives Series Seed Plus Funding to Revolutionize Vaccine Development for Animal Health Genvax Technologies, a pioneering startup in the field of RNA vaccine development for animal health, has successfully closed its Series Seed Plus funding round. This critical…
TriLink BioTechnologies Partners with Avantor to Expand Nucleic Acid Solutions in EMEA Region TriLink BioTechnologies® (TriLink), a global leader in providing life science reagents and services, has announced a strategic partnership with Avantor® Inc. (NYSE: AVTR), a key player in…
Dxcover Secures $6.2 Million in Funding to Drive Growth and Expand Cancer Diagnostics Reach Dxcover Limited, a pioneering clinical-stage diagnostics company known for its cutting-edge multiomic spectral analysis technology (MOSA-Dx™) for the early detection of solid tumor cancers, has announced…
Inhalon Biopharma Advances Breakthrough Inhaled Antibody Treatment for RSV, Targets 2026 Human Trials Inhalon Biopharma, Inc., a clinical-stage company pioneering innovative treatments for acute respiratory infections (ARI), has announced a major milestone in the development of its first-in-class inhaled antibody…
Pfizer’s BRAFTOVI® Combo Boosts Survival in Phase 3 BREAKWATER Trial Pfizer Inc. (NYSE: PFE) has announced promising results from the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin)…
Bioscience B.V., a pioneering commercial-stage specialty pharmaceutical company dedicated to advancing life-changing medicines for rare disease patients across Europe, has announced the appointment of Abdelghani (Abdel) Omari as its first-ever Chief Financial Officer (CFO). This strategic milestone strengthens the company’s…
AliveDx has announced the receipt of IVDR-CE mark for its MosaiQ AiPlex® CTDplus multiplex assay, a significant advancement in the diagnosis and management of Systemic Autoimmune Rheumatic Diseases (SARDs). This multiplex assay enables a syndromic approach, streamlining laboratory workflow while…
Janssen-Cilag International NV, a subsidiary of Johnson & Johnson, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the Subcutaneous European Medicines Agency (EMA) has issued a positive recommendation for an extension of marketing authorization for…
Marquis Who’s Who Recognizes Gail L. Lamoureux, BS, for Excellence in Health Care Gail L. Lamoureux, BS, a dedicated and accomplished professional in the health care industry, has been honored with inclusion in Marquis Who’s Who. This Marquis prestigious recognition…
Vertex Pharmaceuticals Announces Landmark Reimbursement Agreement with NHS England, Expanding Access to CASGEVY® for Sickle Cell Disease Patients Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has revealed a significant milestone in the fight against sickle cell disease (SCD) with the announcement of…